VOR – vor biopharma inc. (US:NASDAQ)

News

Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
Vor Biopharma Inc. (NYSE: VOR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Vor Bio to Participate in Upcoming Investor Conferences
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com